PYM Phytopharm

TIDMIXI

IXICO plc

03 March 2016

IXICO's mehealth(R) deployed in American Academy of Pediatrics quality improvement program for

ADHD patients

Improving pediatric care for children with ADHD in the US

3 March 2016, IXICO plc (Ticker: IXI) ('IXICO' or the 'Company'), the brain health company, is pleased to announce that its mehealth(R) technology has been deployed by the American Academy of Pediatrics ("AAP") as part of its Chapter Quality Network improvement program.

AAP's 2016 quality improvement program initiative aims to improve pediatric ADHD care and patient outcomes. Under this initiative, mehealth(R) for ADHD is being deployed to support pediatricians from six State Chapters in the diagnosis, evaluation, routine assessment and treatment of children with ADHD. It will be used also for the collection of care quality metrics and to assist with training.

Professor Derek Hill, Chief Executive of IXICO, commented: "We are delighted to be participating in the AAP's 2016 initiative, which is focused on the clinical management and care of children and families living with ADHD. We are proud to be working alongside leading partners who have a shared vision of using technology, knowledge and expertise to change the delivery of healthcare and bring meaningful benefits to patients. The prominence and size of the AAP provides a significant opportunity for our mehealth(R) for ADHD product."

The clinical care provided to children with ADHD traditionally relies on parents and teachers completing extensive paper-based assessments. The mehealth(R) platform technology simplifies data collection and facilitates reduced assessment times with the potential for more accurate diagnoses and improved treatment monitoring. Digital healthcare tools enable pediatricians to balance an ever increasing work load whilst delivering the highest standards of care.

A participating physician commented: "Parents and teachers have found that completing paper based Vanderbilt Assessments can be frustrating and time consuming. The mehealth(R) for ADHD product helps to reduce this frustration as mobile data entry makes it convenient to provide inputs that the physician can use in the provision of care."

Enquiries:

 
 IXICO plc                       +44 20 3763 7499 
 Derek Hill, CEO 
 Susan Lowther, CFO 
 
 Peel Hunt LLP (Nominated 
  Adviser and Broker)            +44 20 7418 8900 
 James Steel / Oliver Jackson 
 
 Daniel Stewart & Company 
  (Joint Broker)                 +44 207 776 6550 
 Martin Lampshire / David 
  Coffman 
 
 FTI Consulting Limited 
  (Investor Relations)           +44 20 3727 1000 
 Simon Conway / Mo Noonan 
  / Matthew Moss 
 

Notes to Editors

About IXICO

IXICO's innovative and proprietary digital healthcare technologies help those involved in researching and treating serious diseases to capture and analyse clinical data to make rapid, informed decisions. In clinical research this includes the phenotyping of patients, quantification of disease pathology and measurement of patient outcomes. In clinical practice the mobile health and digital decision support technologies aid diagnosis, patient engagement and monitoring. IXICO is also collaborating with partners to develop companion digital health products targeted at improving patient outcomes.

The Company's brain health focus includes Alzheimer's disease, Huntington's disease, multiple sclerosis, behavioral health, child and adolescent mental health.

More information is available on www.ixico.com

About mehealth(R)

mehealth(R) for ADHD is an evidence-based, comprehensive, and easy-to-use online tool. The mehealth platform integrates web-based and mobile technologies for clinicians and patients, allowing care to be initiated and adapted according to the patients' unique profile and evolving needs. The software has been used in the care of over 12,000 children across the US and has been shown in a randomized trial to improve concordance with the AAP's ADHD clinical guidelines

http://pediatrics.aappublications.org/content/early/2011/10/14/peds.2011-0872].

More information is available on www.mehealth.com

About AAP

AAP is an organization of 62,000 pediatricians committed to the optimal physical, mental, and social health and well-being for all infants, children, adolescents, and young adults. The AAP is organised into a total of 59 chapters across the US.

Attention - Deficit/Hyperactivity Disorder in children and adolescents ("ADHD")

ADHD is one of the most common childhood disorders which currently affects 11% of children aged 4-17 in the United States. The disorder can continue into adolescence and adulthood, causing prolonged academic, conduct, social and mental health problems, as well as high economic costs. Most children with ADHD symptoms are managed by their primary care provider, however, diagnostic processes and treatment plans in this setting often fail to meet evidence-based standards. In 2011, the AAP published a clinical practice guideline relating to pediatric ADHD care: ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/ Hyperactivity Disorder in Children and Adolescents.

www.pediatrics.org/cgi/doi/10.1542/peds.2011-2654

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAFMGGFRZVGVZM

(END) Dow Jones Newswires

March 03, 2016 02:03 ET (07:03 GMT)

Phytopharm (LSE:PYM)
Historical Stock Chart
Von Nov 2024 bis Dez 2024

Phytopharm (LSE:PYM)
Historical Stock Chart
Von Dez 2023 bis Dez 2024